Get started
Author

Margot S. F. Roeten

Observed names: Margot Roeten, Margot S F Roeten, Margot S.F. Roeten, Margot SF Roeten
OpenAlex ID: A5021669770
Positioning of proteasome inhibitors in therapy of solid malignancies
2017 · Margot S. F. Roeten, Jacqueline Cloos, et al. · Cancer Chemotherapy and Pharmacology · 145
PDF
1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1
2023 · Daniela Carbone, Camilla Pecoraro, et al. · Marine Drugs · 44
PDF
(Immuno)proteasomes as therapeutic target in acute leukemia
2017 · Jacqueline Cloos, Margot SF Roeten, et al. · Cancer and Metastasis Reviews · 33
PDF
Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile
2024 · Camilla Pecoraro, Daniela Carbone, et al. · Journal of drug targeting · 15
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
2021 · Margot S.F. Roeten, Johan van Meerloo, et al. · Cells · 13
PDF
Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: Synthesis, mechanistic Insights and promising antitumor and safety profile
2024 · Daniela Carbone, Camilla Pecoraro, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial
2025 · Margot S. F. Roeten, Johan Van Meerloo, et al. · Haematologica
PDF
P329: High Immunoproteasome Activity as Novel Indicator for Sensitivity to Bortezomib-containing Chemotherapy in Acute Lymphoblastic Leukemia Patients From Children’s Oncology Group Trial Aall1231
2023 · Margot Roeten, Suzanne van Dijk, et al. · HemaSphere
High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231
2022 · Margot S.F. Roeten, Johan van Meerloo, et al. · Blood
Works count: 9
Citation count: 252
H-index: 5
I10-index: 5
Year
Topic
Type